ArticleCirculation reports2026
High-Sensitivity C-Reactive Protein and Risk of Recurrent Vascular Events in Patients With Stroke Associated With Complex Aortic Atheroma.
Article in Circulation reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Complex aortic atheroma (CAA) is a high-risk source of ischemic stroke, yet predictors of recurrent vascular events in CAA-related stroke remain poorly defined. We evaluated the prognostic value of high-sensitivity C-reactive protein (hsCRP). Methods and Results: This single-center, prospective, observational registry enrolled consecutive patients with stroke within 1 week of onset. Transesophageal echocardiography (TEE) was not protocol-mandated but used at physician discretion, mainly for embolic-source evaluation. CAA was defined as any plaque ≥4 mm in thickness or a plaque with ulceration or mobile components on TEE. Patients were dichotomized by hsCRP at 3.0 mg/L. The primary outcome was 1-year major adverse cardiovascular events (MACE), including stroke, acute coronary syndrome, and vascular death. Among 1,214 patients, TEE was performed in 335; CAA was identified in 83 (24.8%). Seventy-six with hsCRP data were analyzed, with 1-year follow up obtained in 73 (96.1%). Over 1 year, 17 patients had at least 1 vascular event, yielding an event rate of 23.2%. The incidence of MACE was significantly higher in patients with hsCRP ≥3.0 mg/L than in those with hsCRP <3.0 mg/L (42.2% vs. 15.3%; log-rank P=0.010). In multivariable Cox analysis, hsCRP ≥3.0 mg/L independently predicted MACE (hazard ratio 4.68; 95% confidence interval 1.43-15.32). Conclusions: Elevated hsCRP is independently associated with an increased risk of MACE in CAA-related stroke. hsCRP may aid risk stratification and underscores the role of systemic inflammation in this high-risk subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.